Okomo U, Meremikwu M M
Clinical Services, Medical Research Council Laboratories, Atlantic Boulevard, Fajara, Gambia, P.O. Box 273.
Cochrane Database Syst Rev. 2007 Apr 18(2):CD005406. doi: 10.1002/14651858.CD005406.pub2.
Treating vaso-occlusive painful crises in people with sickle cell disease is complex and requires multiple interventions. Extra fluids are routinely given as adjunct treatment, regardless of the individual's state of hydration with the aim of slowing or stopping the sickling process and thereby alleviating pain.
To determine the optimal route, quantity and type of fluid replacement for people with sickle cell disease with acute painful crises.
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also conducted searches of EMBASE, LILACS and the website www.ClinicalTrials.gov. Date of most recent search of the Group's Haemoglobinopathies Trials Register: February 2007.
Randomised and quasi-randomised controlled trials that compared the administration of supplemental fluids adjunctive to analgesics by any route in people with any type of sickle cell disease during an acute painful episode, under medical supervision (inpatient, day care or community).
No relevant trials have yet been identified.
Sixteen trials were identified by the initial search. Of these, 15 were not suitable for inclusion in this review and one study is awaiting further assessment.
AUTHORS' CONCLUSIONS: Treating vaso-occlusive crises is complex and requires multiple interventions. Extra fluids, generally oral or intravenous, are routinely administered during acute painful episodes to people with sickle cell disease regardless of the individual's state of hydration. Reports of their use during these acute painful episodes do not state the efficacy of any single route, type or quantity of fluid compared to another. However, there are no randomized controlled trials that have assessed the safety and efficacy of different routes, types or quantities of fluid. This systematic review identifies the need for a multicentre randomized controlled trial assessing the efficacy and possible adverse effects of different routes, types and quantities of fluid administered to people with sickle cell disease during acute painful episodes.
治疗镰状细胞病患者的血管阻塞性疼痛危象较为复杂,需要多种干预措施。无论个体的水合状态如何,通常都会额外补充液体作为辅助治疗,目的是减缓或阻止镰变过程,从而减轻疼痛。
确定镰状细胞病急性疼痛危象患者补液的最佳途径、量和类型。
我们检索了Cochrane囊性纤维化和遗传疾病小组试验注册库,该注册库包含从全面的电子数据库检索以及对相关期刊和会议论文摘要集的手工检索中识别出的参考文献。我们还检索了EMBASE、LILACS以及www.ClinicalTrials.gov网站。该小组血红蛋白病试验注册库的最新检索日期为2007年2月。
随机和半随机对照试验,比较在医疗监督下(住院、日间护理或社区),任何类型镰状细胞病患者在急性疼痛发作期间通过任何途径给予补充液体作为镇痛药辅助治疗的情况。
尚未识别出相关试验。
初步检索识别出16项试验。其中,15项不适合纳入本综述,1项研究正在等待进一步评估。
治疗血管阻塞性危象较为复杂,需要多种干预措施。在急性疼痛发作期间,通常会给镰状细胞病患者常规补充额外的液体,一般为口服或静脉注射,而不考虑个体的水合状态。关于在这些急性疼痛发作期间使用液体的报告并未说明任何单一途径、类型或量的液体与其他液体相比的疗效。然而,尚无随机对照试验评估不同途径、类型或量的液体的安全性和疗效。本系统评价表明,需要进行一项多中心随机对照试验,以评估在急性疼痛发作期间给予镰状细胞病患者不同途径、类型和量的液体的疗效及可能的不良反应。